Therapeutic Development Progress
Airway Therapeutics is advancing zelpultide alfa across multiple indications. The therapy is currently in Phase 2b/3 trials for very preterm neonates with bronchopulmonary dysplasia (BPD).
Beyond BPD, the company is actively exploring zelpultide alfa’s potential in a broad spectrum of respiratory, inflammatory, and infectious conditions, including chronic obstructive pulmonary disease (COPD), pneumonia, acute respiratory distress syndrome (ARDS), lung fibrosis, and influenza a virus infection.
